BALTIMORE, FASgen Inc. announced it has successfully expanded the potential use for its serum FAS (fatty acid synthase) ELISA diagnostic research test, FAS-Detect(TM) ELISA for the identification of Non-Alcoholic Steatohepatitis (NASH).
The current diagnostic technique for this disease is a liver needle biopsy. While only for research use presently, FASgen anticipates the opportunity for use of the non-invasive FAS-Detect(TM) ELISA NASH test in the future will be substantial. FAS-Detect(TM) ELISA is a proprietary product of FASgen Diagnostics LLC, an affiliated FASgen company.
AdvertisementNASH commonly occurs as the result of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is now rather common among the obese population, with an estimated 25 million adults harboring NAFLD, with up to 5% of these patients developing NASH. A significant number of NASH patients go on to develop potentially fatal cirrhosis.
These discoveries by FASgen are part of the Company's extensive work in developing therapeutic products to treat obesity by the selective inhibition of FAS and related targets. Identifying patients with NASH in the future using the FAS-Detect(TM) ELISA serum test could select those patients at risk for serious liver disease and those most likely to benefit from proactive therapy.
About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.
The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new a highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders. For more information, visit FASgen's website at www.fasgen.com.
Source: PR Newswire
You May Also Like